The NAD+ Question

— Why 2025's Most Researched Longevity Molecule Isn't What You Think—And Why That Matters

The Molecule Everyone's Talking About

There's a molecule that Silicon Valley executives are injecting. That longevity researchers are studying. That supplement companies are marketing with promises that would make snake oil salesmen blush.

It's called NAD+. And in 2025, it's everywhere.

The claims are seductive: reverse aging, restore energy, prevent Alzheimer's, unlock cellular immortality.

But here's what nobody's telling you: most of it is noise.

Not because NAD+ isn't important—it is. Not because the science isn't real—it's fascinating. But because the gap between what works in mice and what works in humans remains vast. And because the supplements being sold don't always do what the marketing suggests.

This is the story the longevity industry doesn't want you to hear.

Walk into any biohacking conference in 2025 and you'll hear it: NAD+. Tech founders microdosing NMN. Venture capitalists investing in NAD+ clinics. Podcasters debating the merits of sublingual versus oral delivery.

The supplement market has exploded. NMN (nicotinamide mononucleotide), NR (nicotinamide riboside), and even direct NAD+ IV drips are now sold with promises of "cellular rejuvenation" and "age reversal."

Fortune magazine calls them "2025's most exciting supplements." Companies are raising millions. Clinical trials are multiplying.

But if you actually read the research—not the headlines, not the marketing, but the peer-reviewed clinical data—a different picture emerges.

Not "doesn't work." Not "worthless." But limited. Nuanced. Context-dependent.

This is where most articles stop. This is where we begin.

What NAD+ Actually Is

NAD+ (nicotinamide adenine dinucleotide) is one of the most fundamental molecules in biology. It's present in every cell of every living organism.

Think of it as cellular currency—the molecule that allows other processes to happen.

Without NAD+:

• Your mitochondria can't produce ATP (cellular energy)
• Your DNA can't be repaired effectively
• Sirtuins (longevity proteins) can't function
• Cellular stress responses fail

NAD+ isn't optional. It's essential.

The question isn't whether NAD+ matters. It does. The question is: what happens when NAD+ levels decline—and can we meaningfully reverse that decline?

The Decline Nobody Notices Until It's Too Late

Here's what we know for certain: NAD+ levels decline in specific tissues as we age.

Research consistently shows reductions in skeletal muscle, brain tissue, skin, and liver (in some studies). But—and this is crucial—not all tissues show decline, and not all individuals show decline at the same rate.

A 2025 systematic review from Amsterdam UMC found that whole blood NAD+ levels don't consistently decline with age. Some tissues decline dramatically. Others remain stable.

This matters because if NAD+ decline were universal and uniform, boosting it would be straightforward. But it's not. It's tissue-specific, individual-specific, and context-dependent.

The Precursor Puzzle

Since NAD+ itself can't easily cross cell membranes (it's too large and charged), the supplement industry focuses on precursors—smaller molecules your body converts into NAD+.

Nicotinamide (NAM)

The simplest form of vitamin B3. Your body already uses this in the "salvage pathway" to recycle NAD+.

Pros: Cheap, well-studied, safe, readily available in food.
Cons: Can inhibit sirtuins at high doses (the very proteins NAD+ is supposed to activate).

Nicotinamide Riboside (NR)

A more complex precursor that bypasses some metabolic steps.

Pros: Clinical evidence shows it raises NAD+ in blood and muscle. Generally well-tolerated.
Cons: Expensive. Unstable (degrades quickly in water). Clinical benefits in humans remain modest.

Nicotinamide Mononucleotide (NMN)

The darling of the longevity community. Popularized by David Sinclair.

Pros: Direct precursor to NAD+. Animal studies show dramatic benefits.
Cons: Human data still limited. Expensive. Stability concerns. Recent studies suggest it's converted to NAM in the gut before absorption, questioning whether it offers advantages over simpler forms.

The Clinical Reality Check

Let's talk about what actually happened in human trials.

The Alzheimer's Study (2024)

46 older adults with mild cognitive impairment received NAD+ precursors for several months. Result: 7% reduction in tau proteins (a biomarker for Alzheimer's). That sounds promising—except tau reduction didn't translate to cognitive improvement. Participants didn't score better on memory tests. They didn't report feeling sharper. Biomarker changed. Function didn't.

The Muscle Study (2023)

Elderly adults received NR supplementation to test effects on muscle function. Result: Increased NAD+ in muscle tissue. No improvement in strength or endurance. Again: biochemical change without functional benefit.

The Cardiovascular Trials

Some studies showed modest improvements in blood pressure and arterial stiffness with NAD+ precursors. Others showed no effect. The pattern repeats: inconsistent results, modest effects, and significant individual variation.

The Foundational Approach

Here's what the research actually supports—not as speculation, but as demonstrated benefit:

1. Address the Root Causes of NAD+ Depletion

NAD+ doesn't decline in a vacuum. It declines because of chronic inflammation, metabolic dysfunction, oxidative stress, poor sleep, and excessive alcohol consumption. Supplementing NAD+ precursors while ignoring these factors is like refilling a leaking bucket. Fix the leaks first.

2. Support NAD+ Synthesis Pathways

Your body makes NAD+ from multiple precursors. Supporting the entire system works better than focusing on one molecule.

Omega-3 (EPA/DHA) — Reduces inflammation, preserving NAD+ for productive cellular processes rather than damage control.

Omega-3 Softgels

Magnesium — Required for hundreds of enzymatic reactions, including those in NAD+ metabolism. Deficiency impairs ATP production, creating a vicious cycle.

Magnesium Complex

B-Complex Vitamins — Provide the building blocks (niacin, B6, B12) needed for NAD+ synthesis pathways.

Vitamineral Complex

3. Activate Sirtuins Through Complementary Pathways

Sirtuins (the "longevity proteins") depend on NAD+. But you can support their activity through multiple mechanisms: Resveratrol activates SIRT1 directly. Pterostilbene is resveratrol's more bioavailable cousin. Quercetin is a senolytic compound that removes damaged cells, reducing the inflammatory burden that depletes NAD+.

4. Prioritize Metabolic Health

The strongest predictor of NAD+ response isn't age—it's metabolic status. People with insulin resistance, obesity, chronic inflammation, or poor cardiovascular health show the greatest improvements from NAD+ support. Which suggests: NAD+ supplementation may be most valuable as metabolic repair, not anti-aging magic.

The GIVORY Perspective on NAD+ and Longevity

At GIVORY People, we don't chase trends. We follow evidence.

NAD+ science is fascinating. The potential is real. But the current state of human research doesn't support the hyperbolic claims flooding the market.

What does the evidence support? A foundational approach: Reduce inflammation (Omega-3, Turmeric, Spirulina). Support mitochondrial function (Shilajit, CoQ10, Magnesium). Optimize metabolic health (Ashwagandha for stress, Vitamin D for hormonal balance). Ensure micronutrient sufficiency (B-vitamins, Zinc, comprehensive multivitamins).

These interventions create the conditions where NAD+ metabolism can function optimally—without relying on expensive, unproven precursors.

Does this mean we'll never offer NAD+ precursors? Not necessarily. If future research demonstrates consistent, meaningful benefit in well-designed human trials—and if we can source forms with genuine bioavailability and stability—we'll consider it. But we won't market hope. We won't sell promise. We'll only offer what the science genuinely supports.

Sources of Influence

Our approach grew from rigorous study and the desire to unite science, behaviour, and awareness.

Scientific Research — NAD+ and Longevity

Primary sources:

• NAD+ precursor supplementation in human ageing (Nature Metabolism, 2025)
• Targeting NAD+ in the clinic (Nature Aging, 2025)
• Therapeutic perspective of NAD+ precursors (Biochemical and Biophysical Research, 2024)

The GIVORY Takeaway

NAD+ is important. The research is legitimate. The potential exists. But 2025's longevity boom has outpaced the science.

The individuals thriving aren't those microdosing the latest precursor. They're those addressing the fundamentals: managing stress, sleeping deeply, eating anti-inflammatory foods, moving regularly, supporting cellular infrastructure.

This isn't sexy. It doesn't sell itself with promises of "reversing aging." But it works. Not because of one molecule. Because of intelligent systems.

That's the GIVORY difference.